The Elmiron eye-damage lawsuit filed by Kimberly Pelzczar against Teva Pharmaceuticals USA is still active. Kimberly began taking the drug in 2005 and began noticing serious vision problems within a short period of time. She began to visit doctors in 2015 and was diagnosed with permanent vision loss and retinal injury.
Table of Contents
Although new Elmiron eye damage lawsuits have slowed down in recent months, there are still 1,725 Elmiron lawsuits pending in federal class action and in state courts. While these figures may not be accurate, they still represent a significant increase compared to the number of plaintiffs who filed cases during the same time last year. Elmiron is now the subject of a new study that will look at whether the drug caused maculopathy, a condition characterized by a loss of vision. This study by Northwestern University will examine the medical records of 131 Elmiron patients and review the images of 40 Elmiron patients who underwent fundus examinations. This new report is expected to further validate the lawsuits filed by patients.
Although the Elmiron lawsuit is still in its infancy, the evidence that supports it is compelling and could spur a wave of lawsuits against the drug manufacturer. In fact, the drug is believed to cause damage to the retina, and hundreds of Elmiron eye damage lawsuits are expected to be filed in the coming years. If you or a loved one has suffered from the side effects or vision loss associated with Elmiron, contact a law firm to find out your legal options. The law office will offer free consultations for those who are interested in filing an Elmiron lawsuit.
Optic neuritis is a potentially serious eye disease, and it can occur due to certain drugs, such as Elmiron. Elmiron is a prescription drug manufactured by Janssen Pharmaceuticals. It can affect the retina in the eye, which results in degeneration and eventual death of the eye tissue. It can also affect visual acuity and sensitivity over an extended period of time.
The lawsuit claims that Janssen Pharmaceuticals, the company that manufactures Elmiron, misrepresented the dangers of the drug, which can result in eye damage. While it is difficult to hold a drug manufacturer responsible for causing harm to patients, a lawyer with experience handling these cases can help you fight for compensation.
The case was filed in March 2020 by Kimberly Pelzczar, who used Elmiron for over six years. In the lawsuit, Pelzczar claims that her vision began to deteriorate quickly. She sought medical attention between 2015 and 2019, and was diagnosed with macular degeneration and permanent vision loss.
Pigmentary maculopathy is an eye disease that occurs in as many as 25% of patients treated with Elmiron. The condition is often misdiagnosed as pattern dystrophy or age-related macular degeneration. However, further testing can reveal a diagnosis of pigmentary maculopathy.
The FDA warned that Elmiron could cause the condition by changing the color of pigment cells in the retina. This problem has been linked to long-term use of the drug. The damage caused by pigmentary maculopathy is similar to that caused by age-related macular degeneration of the retina. Most cases occurred after use of the drug for at least three years, although some cases were shorter.
The Elmiron eye damage lawsuit was first filed in federal court in Oregon. Later, the lawsuit was transferred to the Elmiron MDL, which is similar to a large class action. This type of litigation is still in the early stages. It is possible that more cases will be filed in the future.
Class action lawsuit
If you are a victim of eye damage caused by Elmiron, you may be eligible to file a class action lawsuit against the manufacturer of the drug. Elmiron has been linked to retinal maculopathy, a degenerative condition that causes vision loss and can lead to blindness. Some symptoms of this condition include blurred vision, trouble reading, dark spots, and trouble focusing. In extreme cases, you may also lose your sight altogether.
The Elmiron eye damage class action lawsuit was one of the hottest mass torts of the summer, with 365 new plaintiffs adding their names to the MDL from June 15 to July 15. The federal court system has scheduled several early test trials in 2023 and these will have a large impact on the final Elmiron settlement amount. While bellwether trials are not binding on other claims, they will provide important information about how juries react to evidence and testimony.
The lawsuit is filed in Connecticut on behalf of individuals who suffered from the eye damage caused by Elmiron. The lawsuit alleges that the manufacturer of Elmiron did not adequately warn doctors and patients about the risks of the medication. Even though the drug was designed to treat interstitial cystitis and other eye problems, the company did not screen for potential side effects, including eye damage. As a result, many people have suffered from vision problems.